Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$19.05 USD
-0.12 (-0.63%)
Updated May 24, 2024 04:00 PM ET
After-Market: $19.05 0.00 (0.00%) 4:46 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
KNSA 19.05 -0.12(-0.63%)
Will KNSA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for KNSA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KNSA
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
KNSA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice
Other News for KNSA
Market Underestimates Kiniksa Pharmaceuticals’ Abiprubart Potential Despite Positive Industry Indicators
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
Kiniksa initiated with bullish view at Wells Fargo, here's why
Kiniksa Pharmaceuticals (NASDAQ:KNSA): New Drug Treatment Could Have Upside Potential
Kiniksa Pharmaceuticals Faces Capital Raising Hurdles Amid Stricter UK Shareholder Voting Laws